1. The Center of Cardiovascular Diseases, the First Hospital of Jilin University, Changchun 130021, China.
2. Pediatric Research Institute, the Department of Pediatrics of University of Louisville, Louisville, KY 40202, USA.
3. Department of Nephrology, the First Hospital of Jilin University, Changchun 130021, China.
4. Department of Respiratory Medicine, the First Hospital of Jilin University (Eastern Division), Changchun 130031, China.
5. Department of Pharmacology and Toxicology, the University of Louisville, Louisville, KY 40202, USA.
Mediator complex subunit 13 (MED13, previously known as THRAP1 and TRAP240) is a subunit of the cyclin-dependent kinase 8 (CDK8) kinase module in the eukaryotic mediator complex. MED13 has been known to play critical roles in cell cycle, development, and growth. The purpose of this review is to comprehensively discuss its newly identified potential roles in myocardial energy metabolism and non-metabolic cardiovascular diseases. Evidence indicates that cardiac MED13 mainly participates in the regulation of nuclear receptor signaling, which drives the transcription of genes involved in modulating cardiac and systemic energy homeostasis. MED13 is also associated with several pathological conditions, such as metabolic syndrome and thyroid disease-associated heart failure. Therefore, MED13 constitutes a potential therapeutic target for the regulation of metabolic disorders and other cardiovascular diseases.
Keywords: MED13, cardiovascular diseases, energy metabolism